Loading organizations...
§ Private Profile · Waltham, MA, USA
Biopharmaceutical company developing T-cell receptor engineered therapies.
TScan Therapeutics has raised $160.0M across 2 funding rounds.
TScan Therapeutics has raised $160.0M in total across 2 funding rounds.
TScan Therapeutics has raised $160.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 25, 2021 | $100M Series C | — | 6 Dimensions Capital, Bessemer Venture Partners, BlackRock, GV, Longwood Fund, Novartis, Pitango HealthTech, RA Capital Management | Announced |
| Jan 9, 2020 | $60M Series B | — | 6 Dimensions Capital, Astellas Venture Management, Bessemer Venture Partners, DRX Capital, GV, Longwood Fund, Novartis Institutes For Biomedical Research, Pitango Venture Capital | Announced |
TScan Therapeutics has raised $160.0M in total across 2 funding rounds.
TScan Therapeutics's investors include 6 Dimensions Capital, Bessemer Venture Partners, BlackRock, Google Ventures, Longwood Fund, Novartis, Pitango HealthTech, RA Capital Management, Astellas Venture Management, dRx Capital, Novartis Institutes for Biomedical Research, Pitango Venture Capital.